Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2/3 1Phase 2 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Conditions

Breast Neoplasms 1236Neoplasms 1040Carcinoma, Non-Small-Cell Lung 861Prostatic Neoplasms 692Colorectal Neoplasms 614Lung Neoplasms 578Neoplasm Metastasis 439Multiple Myeloma 425Leukemia, Myeloid, Acute 401Pancreatic Neoplasms 376Ovarian Neoplasms 364Melanoma 320Carcinoma, Hepatocellular 288Recurrence 276Squamous Cell Carcinoma of Head and Neck 275Brain Neoplasms 266Glioblastoma 247Head and Neck Neoplasms 244Stomach Neoplasms 239Carcinoma, Renal Cell 228Precursor Cell Lymphoblastic Leukemia-Lymphoma 227Lymphoma 225Triple Negative Breast Neoplasms 219Hematologic Neoplasms 209Endometrial Neoplasms 209Urinary Bladder Neoplasms 202Lymphoma, Non-Hodgkin 197Uterine Cervical Neoplasms 194Sarcoma 190Glioma 190

Interventions

Alpelisib 2mirdametinib 1Injections, Intralesional 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lymphatic Abnormalities × 90 days × Clear all
NCT05948943 2026-06-02

EPIK-L1

Novartis

Phase 2/3 Recruiting
232 enrolled

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

NCT05983159 2026-05-05

TARGET-VM

Murdoch Childrens Research Institute

Phase 2 Recruiting
50 enrolled

Arteriovenous Malformations, Lymphangioma, Skin Diseases, Vascular, Lymphangioma, Cystic, Lymphatic Abnormalities, Vascular Malformations

NCT07189832 2026-04-28

Bleomycin Intralesional Injections of Cystic Hygromas

Delta University for Science and Technology

Phase NA Completed
30 enrolled

Lymphangioma, Cystic, Lymphatic Abnormalities

NCT06239480 2026-03-27

SELVA

Palvella Therapeutics, Inc.

Phase 3 Active not recruiting
51 enrolled

Congenital Abnormalities, Lymphangioma, Lymphatic Abnormalities, Vascular Malformations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡